Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
Nephrons01:10

Nephrons

The kidneys are intricate organs with millions of working units known as nephrons. Each nephron features two major structures: the renal corpuscle, which facilitates blood plasma filtration, and the renal tubule, which handles the glomerular filtrate. Blood supply is directly linked to the nephrons. The renal corpuscle consists of the glomerulus, a capillary network, and the Bowman's capsule, a double-walled epithelial structure that encases the glomerulus. The filtering of blood plasma happens...
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Practical Guide to PSMA PET Radiopharmaceuticals for Prostate Cancer Imaging, From the AJR Special Series on Molecular Imaging.

AJR. American journal of roentgenology·2026
Same author

Development and Implementation of a Radiation Safety Screening Protocol for a Clinical Study Using Amyloid Positron Emission Tomography Imaging.

Ochsner journal·2026
Same author

Integration of PSMA PET into the New Recommendations from Prostate Cancer Working Group 4 for Prostate Cancer Trials.

Journal of nuclear medicine technology·2026
Same author

Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

An intra-patient contemporaneous comparison of <sup>18</sup>F-piflufolastat and <sup>18</sup>F-flotufolastat urinary radioactivity and pelvic region detection rates in men with low PSA biochemical recurrence of prostate cancer after radical prostatectomy.

European journal of nuclear medicine and molecular imaging·2026
Same author

ACR Appropriateness Criteria® Evaluation of Cardiac Masses.

Journal of the American College of Radiology : JACR·2026
Same journal

Cardiovascular Magnetic Resonance: Innovation, Integration, and Clinical Impact.

Magnetic resonance imaging clinics of North America·2026
Same journal

Advances and Innovations in Cardiovascular Magnetic Resonance.

Magnetic resonance imaging clinics of North America·2026
Same journal

The Future of Cardiac Magnetic Resonance: Navigating Ultra-High and Low-Field Imaging (Part 2).

Magnetic resonance imaging clinics of North America·2026
Same journal

Artificial Intelligence Applications in Cardiac MR Imaging.

Magnetic resonance imaging clinics of North America·2026
Same journal

Climate Change and Globally Sustainable Cardiovascular Magnetic Resonance.

Magnetic resonance imaging clinics of North America·2026
Same journal

Strain Imaging in Heart Failure.

Magnetic resonance imaging clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Jun 24, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Nephrogenic systemic fibrosis.

Jeffrey C Weinreb1, Phillip H Kuo

  • 1Department of Diagnostic Radiology, Yale University School of Medicine, 333 Cedar Street, P.O. Box 208042, New Haven, CT 06520-5913, USA. jeffrey.weinreb@yale.edu

Magnetic Resonance Imaging Clinics of North America
|April 15, 2009
PubMed
Summary
This summary is machine-generated.

Gadolinium-based contrast agents (GBCAs) are linked to nephrogenic systemic fibrosis (NSF), a severe disease. This article reviews the GBCA-NSF relationship, prevention strategies, and FDA recommendations for patient safety.

Related Experiment Videos

Last Updated: Jun 24, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Area of Science:

  • Nephrology
  • Radiology
  • Pharmacology

Background:

  • Nephrogenic systemic fibrosis (NSF) is a serious condition associated with gadolinium-based contrast agents (GBCAs).
  • Understanding the link between GBCAs and NSF is crucial for patient safety in medical imaging.
  • Previous research indicates a correlation between GBCA exposure and the development of NSF.

Purpose of the Study:

  • To elucidate the association between intravenous gadolinium-based contrast agents (GBCAs) and nephrogenic systemic fibrosis (NSF).
  • To address common questions regarding the relationship between GBCAs and NSF.
  • To present the policy for NSF prevention and patient screening at Yale-New Haven Hospital.

Main Methods:

  • Literature review on the association between GBCAs and NSF.
  • Discussion of clinical observations and reported cases.
  • Analysis of institutional policies and FDA recommendations.

Main Results:

  • A clear association exists between exposure to GBCAs and the development of NSF.
  • NSF is a debilitating and potentially fatal condition.
  • Specific patient populations are at higher risk.

Conclusions:

  • Healthcare providers must be aware of the risks associated with GBCAs.
  • Implementing preventative measures and screening protocols is essential for at-risk patients.
  • Adherence to FDA guidelines can mitigate the risk of GBCA-induced NSF.